Plaque psoriasis treatments compared by PASI response
Share of patients with moderate-to-severe plaque psoriasis reaching PASI 75, 90 or 100 at weeks 10–16. Hover or tap a bar for dosing and data source.
Response level:
Network meta-analysis estimate (comparable)
Single-trial result (not directly comparable)
PASI 75/90/100 = at least a 75%, 90% or 100% (complete) improvement in the Psoriasis Area and Severity Index from baseline. "Not reported" means the trial didn't publish that level. Phototherapy, topical creams, and drugs approved only outside Australia/US/EU are not included.
Sources
The number after each treatment's source in the hover text matches this list.
- Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258–269. doi:10.1001/jamadermatol.2019.4029. PubMed 32022825. Used for: risankizumab, ixekizumab, brodalumab, guselkumab, secukinumab, infliximab, certolizumab, ustekinumab, adalimumab, tildrakizumab, etanercept, apremilast, dimethyl fumarate, placebo (network meta-analysis, weeks 10–16).
- Armstrong A, Fahrbach K, Leonardi C, et al. Efficacy of bimekizumab and other biologics in moderate to severe plaque psoriasis: a systematic literature review and a network meta-analysis. Dermatol Ther (Heidelb). 2022;12(8):1777–1792. doi:10.1007/s13555-022-00760-8. Used for: bimekizumab (weeks 10–16).
- Bissonnette R, et al. Oral icotrokinra for plaque psoriasis in adults and adolescents (ICONIC-LEAD). N Engl J Med. 2025;393:1784–1795. Article PDF. Used for: icotrokinra (week 16).
- Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88(1):29–39. PubMed. Used for: deucravacitinib PASI 75 (58.4%, week 16).
- ICONIC-ADVANCE 1: icotrokinra vs placebo vs deucravacitinib, phase 3 (Johnson & Johnson). Results summary: 2 Minute Medicine; J&J Medical Connect. Used for: deucravacitinib PASI 90 (30%) and PASI 100 (11%), week 16.
- Warren RB, Mrowietz U, von Kiedrowski R, et al. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10068):528–537. doi:10.1016/S0140-6736(16)32127-4. Used for: methotrexate (week 16).
- Heydendael VMR, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med. 2003;349(7):658–665. doi:10.1056/NEJMoa021359. Used for: ciclosporin (PASI 75 71%, PASI 90 33%; response reached at any point during 16 weeks, n=42).
- Xu K, Yuan P, Jia S, et al. Efficacy and safety of cyclosporine A combined with acitretin in moderate-to-severe plaque psoriasis: a randomized controlled trial. Front Med (Lausanne). 2025;12:1667058. doi:10.3389/fmed.2025.1667058. Used for: acitretin monotherapy arm (PASI 75 70.6%, PASI 90 15.7% at week 12; n=102 completers, ~0.4 mg/kg/day).
- Dogra S, Jain A, Kanwar AJ. Efficacy and safety of acitretin in three fixed doses of 25, 35 and 50 mg in adult patients with severe plaque type psoriasis: a randomized, double blind, parallel group, dose ranging study. J Eur Acad Dermatol Venereol. 2013;27(3):e305–e311. PubMed 22816881. Acitretin context: PASI 75 at 12 weeks was 47%, 69% and 53% at 25, 35 and 50 mg/day.
- A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis. BMC Dermatol. 2016;16:11. doi:10.1186/s12895-016-0048-z. Acitretin context: PASI 75 22.2% at week 24 on 20 mg/day.
- Chiricozzi A, Panduri S, Dini V, et al. Optimizing acitretin use in patients with plaque psoriasis. Dermatol Ther. 2017;30(2):e12453. Record. Acitretin context (real-world clinic data): PASI 75 48%, PASI 90 28%, PASI 100 14%.
- Sbidian E, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (living review, 2025 update). Cochrane Database Syst Rev. CD011535. Cochrane Library. Background: confirms bimekizumab, infliximab, ixekizumab and risankizumab as most effective for PASI 90.
Cross-trial comparisons have limits: hatched bars come from single trials with different populations and placebo rates, so they can't be ranked precisely against the meta-analysis estimates. Short-term PASI is only one factor in choosing a treatment — joint disease, other conditions (e.g. IBD, liver disease), dosing, safety and access all matter. Not medical advice; talk to your dermatologist.